Common Contracts
10 similar Securities Purchase Agreement contracts by Aclaris Therapeutics, Inc., Day One Biopharmaceuticals, Inc., Inhibikase Therapeutics, Inc., others
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 18th, 2024 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 18, 2024, by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 4th, 2024 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2024, by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 4th, 2024 • Neurogene Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2024, by and among Neurogene Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENT2Securities Purchase Agreement • October 20th, 2024
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 20[ ], by and among [ ], a [type of entity] [incorporated/organized] under the laws of [jurisdiction of incorporation/organization] (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 6th, 2024 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 6, 2024, by and among Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 30th, 2024 • Day One Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 30, 2024, by and among Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 3rd, 2024 • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 20[ ], by and among [ ], a [Delaware corporation] (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 13th, 2024 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 3rd, 2024 • Summit Therapeutics Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 3, 2024, by and among Summit Therapeutics Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
